| abstract |
Novel 2,4,5-triarylimidazole compounds of formula:n nwhereinn R 1 is pyrimidinyl, optionally substituted with one or twonsubstituents each of which is independently selected form C 1-4 nalkyl, halo, C 1-4 alkoxy, C 1-4 alkylthio, NH 2 , mono- orndi-C 1-6 -alkylamino and a N-heterocyclyl ring which ring hasnfrom 5 to 7 members, and optionally contains an additional heteroatomnselected from oxygen, sulfur and NR 22 ; R 2 is R 8 or -OR 12 ; R 3 is -X a P(Z)(X b R 13 ) 2 or Q-(Y 1 ) t ; R 4 is phenyl, naphth-1-yl or naphth-2-yl; Q is an aryl or heteroaryl group; Y 1 is independently selected from hydrogen, C 1-5 nalkyl, halo-substituted C 1-5 alkyl; R 8 is hydrogen, heterocyclyl, heterocyclylalkyl ornR 11 ; R 11 is C 1-10 alkyl, halo-substitutednC 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl,nC 5-7 cycloalkenyl, aryl, arylalkyl, heteroaryl ornheteroarylalkyl; nprocesses for the preparation thereof, the use thereof in treatingncytokine mediated diseases and pharmaceutical compositions for use innsuch therapy. |